Uniqure (QURE) Lifted to “Buy” at BidaskClub

Uniqure (NASDAQ:QURE) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Saturday.

A number of other research firms have also recently issued reports on QURE. HC Wainwright set a $28.00 price target on shares of Uniqure and gave the company a “buy” rating in a report on Thursday, December 7th. Janney Montgomery Scott started coverage on shares of Uniqure in a report on Wednesday, January 3rd. They set a “buy” rating and a $25.00 price target for the company. Zacks Investment Research cut shares of Uniqure from a “buy” rating to a “hold” rating in a report on Saturday, February 3rd. Oppenheimer reaffirmed a “hold” rating on shares of Uniqure in a research report on Friday, November 24th. Finally, ValuEngine lowered shares of Uniqure from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $21.38.

How to Become a New Pot Stock Millionaire

Shares of QURE stock opened at $23.07 on Friday. The company has a current ratio of 8.46, a quick ratio of 8.46 and a debt-to-equity ratio of 0.22. Uniqure has a fifty-two week low of $4.72 and a fifty-two week high of $27.19. The stock has a market cap of $730.95, a PE ratio of -7.85 and a beta of 0.09.

In related news, CEO Matthew C. Kapusta sold 21,690 shares of the stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $19.87, for a total value of $430,980.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Matthew C. Kapusta sold 39,169 shares of the stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $21.72, for a total transaction of $850,750.68. Following the completion of the transaction, the chief executive officer now directly owns 439,764 shares of the company’s stock, valued at approximately $9,551,674.08. The disclosure for this sale can be found here. Insiders have sold 80,679 shares of company stock valued at $1,666,527 in the last ninety days. 0.73% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of QURE. Macquarie Group Ltd. raised its position in Uniqure by 660.1% in the fourth quarter. Macquarie Group Ltd. now owns 532,049 shares of the biotechnology company’s stock worth $10,423,000 after purchasing an additional 462,049 shares in the last quarter. BlackRock Inc. raised its position in Uniqure by 999.6% in the fourth quarter. BlackRock Inc. now owns 468,422 shares of the biotechnology company’s stock worth $9,177,000 after purchasing an additional 425,823 shares in the last quarter. RTW Investments LP acquired a new position in Uniqure in the fourth quarter worth about $7,905,000. Prosight Management LP acquired a new position in Uniqure in the fourth quarter worth about $5,578,000. Finally, Bogle Investment Management L P DE acquired a new position in Uniqure in the fourth quarter worth about $3,553,000. 43.98% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3300837/uniqure-qure-lifted-to-buy-at-bidaskclub.html.

About Uniqure

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease.

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Harris  and FLIR Systems  Critical Comparison
Harris and FLIR Systems Critical Comparison
Brink’s  Releases FY18 Earnings Guidance
Brink’s Releases FY18 Earnings Guidance
Accelerate Diagnostics  versus Horiba  Critical Comparison
Accelerate Diagnostics versus Horiba Critical Comparison
Analysts Anticipate Radware  Will Post Earnings of $0.05 Per Share
Analysts Anticipate Radware Will Post Earnings of $0.05 Per Share
Zacks: Brokerages Expect Columbia Banking System, Inc.  Will Announce Quarterly Sales of $142.70 Million
Zacks: Brokerages Expect Columbia Banking System, Inc. Will Announce Quarterly Sales of $142.70 Million
Zacks: Analysts Expect Hydrogenics  Will Post Quarterly Sales of $10.20 Million
Zacks: Analysts Expect Hydrogenics Will Post Quarterly Sales of $10.20 Million


© 2006-2018 Ticker Report. Google+.